1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Caplin Point Laboratories Limited

Caplin Point Laboratories Limited

2,249.10
INR
+27.50
(+1.24%)
87.70EPS
30.08P/E
199.61BMarket Cap
Nov 05Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
22.91
33.32
- -
51.65
69.53
83.71
111.65
138.58
167.69
191.72
221.18
252.81
285.66
297.77
Basic EPS, GAAP
3.42
5.43
- -
12.65
19.16
23.35
28.42
32.03
39.61
49.62
60.19
70.57
84.36
87.31
Free Cash Flow per Basic Share
1.76
3.23
- -
5.56
8.8
11.03
5.91
35.51
44.48
10.27
22.73
56.89
68.84
- -
Dividend per Share
0.58
0.96
- -
0.84
1.5
2
4.3
0.4
3
4
4.5
5
6
- -
Book Value per Share
8.17
12.34
17.93
29.74
48.12
78.93
115.45
146.91
195.8
247.75
304.93
375.01
471.82
- -
Tangible Book Value per Share
8.09
12.21
17.85
29.56
47.85
78.66
114.78
145.94
194.37
246.28
303.28
372.96
464.74
- -
Basic Weighted Avg Shares
76
76
76
76
76
76
76
76
76
76
76
76
76
76
Sales/Revenue/Turnover
1,731
2,518
- -
3,902
5,256
6,329
8,445
10,483
12,694
14,538
16,796
19,212
21,714
22,635
Operating Margin (%)
19.3
21.16
- -
28.69
33.56
32.98
27.15
27.98
27.4
27.4
29.83
30.55
31.99
31.33
Depreciation Expense
35
84
- -
133
190
234
316
370
469
450
534
660
728
760
Net Income, GAAP
258
410
- -
956
1,448
1,766
2,150
2,423
2,998
3,763
4,571
5,363
6,412
6,637
Effective Tax Rate (%)
27.34
22.97
- -
21.04
23.22
22.18
20.18
19.83
20.05
16.48
18.25
20.05
19.07
19.16
Profit Margin (%)
14.93
16.3
- -
24.5
27.55
27.9
25.46
23.11
23.62
25.88
27.22
27.91
29.53
29.32
Working Capital
-590
-431
-1
659
1,954
4,076
6,782
8,717
10,901
12,842
15,621
18,280
21,997
- -
LT Debt
21
9
7
5
3
3
13
5
12
9
9
29
21
- -
Total Equity
619
935
1,357
2,251
3,639
6,330
9,566
12,034
15,099
19,073
23,468
28,864
36,308
- -
Return on Invested Capital (%)
43.82
51.8
- -
48.44
45.88
32.56
22.47
21.17
20.34
19.41
19.19
17.8
17.18
- -
Return on Capital (%)
46.66
51.92
- -
52.71
49.12
35.4
26.42
21.14
21.35
21.97
21.28
20.31
19.41
- -
Return on Common Equity (%)
49.29
52.97
- -
53.09
49.2
36.75
29.25
24.42
23.11
22.37
21.79
20.76
19.92
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
26
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
21
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
76
76
76
Market Capitalization
139,717
114,382
199,607

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
25,857
- -
Cash, Cash Equivalents & STI
- -
9,918
- -
Accounts Receivable, Net
- -
8,258
- -
Inventories
- -
4,289
- -
Total Current Liabilities
- -
3,860
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
26
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.2%
24.72%
25.79%
Free Cash Flow
- -
48.32%
21.02%
Net Income, GAAP
- -
21.53%
19.57%
Sales/Revenue/Turnover
- -
15.71%
13.02%
Total Cash Common Dividend
- -
145.28%
20.06%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
4,590
4,831
4,930
5,025
19,212
2026
5,102
- -
5,428
6,002
21,714
2027
6,104
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
16.32
17.22
18.28
18.75
70.57
2026
20.1
- -
21.56
22.38
84.36
2027
23.27
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
5
2026
- -
- -
- -
- -
6
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sridhar Ganesan
Full Time Employees
5,455
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Ashvich Tower Chennai TN India 600096
IPO Date
Nov 16, 1994
Website
caplinpoint.net
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Caplin Point Laboratories Limited manufactures and markets a broad portfolio of pharmaceutical formulations, including liquid and lyophilized vials, pre-filled syringes, ophthalmic droppers, pre-mix bags, tablets, dry syrups, softgels, capsules, suppositories, liquid syrups, emulsion injections, topicals, and sachets; the company serves regulated markets such as the US and EU as well as emerging markets in Latin America, Francophone Africa, the Caribbean, Southeast Asia, and beyond, with over 4,000 product licenses across 36 therapeutic segments covering more than 65% of the WHO essential drug list. Founded in 1990 and headquartered in Chennai, India, with manufacturing facilities in Puducherry, Gummidipoondi, Visakhapatnam, and near Chennai, as well as subsidiaries including Caplin Steriles Limited, Caplin Point Far East Ltd, and various Latin American entities, Caplin Point operates a fully integrated model emphasizing generics, branded generics, injectables, ophthalmics, softgels, and oncology products for hospitals, wholesalers, retail, and institutional customers targeting the bottom of the pyramid. Recent developments include the June 2025 acquisition of Triwin Pharma S.A. DE C.V. in Mexico by subsidiary Caplin Point Far East to enable government tenders and a stock-and-sale model; the acquisition of Neoethicals Chile SpA; USFDA approval for Brimonidine-Timolol ophthalmic solution by Caplin Steriles in February 2025; launches of the first RTU bag, ophthalmic emulsion, and injectable emulsion products; filing of 30+ products in Mexico with 13 approvals and a 60+ pipeline; first insulin approval in Central America; establishment of private market sales via an owned warehouse in Chile; over 30 planned US product launches in FY26 via Caplin Steriles USA Inc., which has achieved $2.5 million revenue since inception; ongoing capex of over Rs 1,000 crore nearing completion for expanded capacities in lyophilized injectables, dual-chamber syringes, oncology API, and backward integration via API plants in Visakhapatnam and Thervoy; and plans to file GLP-1 products, biosimilars, and first DMFs in emerging and regulated markets.